Candi5V
/ LimmaTech Biologics
- LARVOL DELTA
Home
Next
Prev
1 to 2
Of
2
Go to page
1
December 20, 2024
Assessing the Safety, Immune Response, and Early Efficacy of a Candida Vaccine in Women with Recurrent Vulvovaginal Candidiasis: a Randomized Controlled Study
(clinicaltrials.gov)
- P1/2 | N=251 | Recruiting | Sponsor: LimmaTech Biologics AG | Trial completion date: Dec 2025 ➔ Dec 2026 | Trial primary completion date: Dec 2025 ➔ Dec 2026
Trial completion date • Trial primary completion date • Candidiasis • Vaginitis
January 04, 2024
Assessing the Safety, Immune Response, and Early Efficacy of a Candida Vaccine in Women With Recurrent Vulvovaginal Candidiasis: A Randomized Controlled Study
(clinicaltrials.gov)
- P1/2 | N=251 | Recruiting | Sponsor: LimmaTech Biologics AG
New P1/2 trial • Candidiasis • Vaginitis
1 to 2
Of
2
Go to page
1